All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-01-18T16:10:28.000Z

Sirolimus vs tacrolimus in GvHD prophylaxis following haploidentical allo-HCT: a retrospective analysis

Jan 18, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in GvHD prophylaxis.

Bookmark this article

The GvHD Hub is pleased to present a visual abstract summarizing key findings from a retrospective analysis comparing graft-versus-host disease cyclophosphamide-based prophylaxis posttransplant with sirolimus vs tacrolimus in adult patients undergoing haploidentical allogeneic hematopoietic cell transplantation.1 Most patients were diagnosed with acute myeloid leukemia and a higher proportion of patients in the sirolimus cohort were aged >60 years.

The retrospective study was recently published by Elmariah et al.1 in Transplantation and Cellular Therapy.


Visual Abstract

To download this visual abstract, click below.

Download here

  1. Elmariah H, Otoukesh S, Kumar A, et al. Sirolimus is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide. Transplant Cell Ther. 2023. Online ahead of print. DOI: 1016/j.jtct.2023.11.010

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox